department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Nkarta, Inc. ($NKTX) · pharmadog

PUBLIC COMPANY

$NKTXNkarta, Inc.

South San Francisco, CA, USupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

1

marketed

0

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Phase 2

belacabnagene franleucel

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculiti…

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

2 open roles at Nkarta, Inc. →

Where Nkarta, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaImmunology & Inflammation 2

departmentQuality 1 R&D / Discovery 1

News

no news has mentioned this company yet

identifiers

ticker

$NKTX

SEC CIK

0001787400

country

US

source

sec_tickers

top tags

mentioned in

0news items

entity-linker matched

Active trials

phase2A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)recruitingn=120
phase1NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancersactive not recruitingn=150
phase2A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)recruitingn=144
phase1NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDSactive not recruitingn=61

$NKTX

Data sources

last refreshed 5m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?